Recap: Highlighed Sessions From Day 2 of Asembia

Day 2 of the Asembia AXS26 Summit continued to explore the intersection of clinical innovation, shifting market dynamics, and the digital evolution of patient engagement. These sessions highlighted how the pharmaceutical industry is moving toward a future defined by high-value mega-blockbuster therapies and a patient-centric commercial model that prioritizes longitudinal care over transactional prescribing.

Session 1: Digital Innovation and the Human Touch in Specialty Pharmacy

This session¹ addressed the paradox of increasing technological automation alongside the growing need for personalized patient support. Experts from AcariaHealth Specialty Pharmacy argued that although specialty pharmacy is becoming more complex, the goal of digital tools should be to protect the human touch rather than replace it.

“I think it’s really imperative that we build this specialty pharmacy engagement with patient-centric mindsets; that's very much a focus on how a patient wants to be engaged with, when they want to be engaged with, and not just pushing digital engagement their way where it doesn't make sense to do so,” Jennie Iverson, PhD, vice president of product and clinical strategy, AcariaHealth Specialty Pharmacy, said in the session.

Currently, many patient journeys remain fragmented and reactive, especially during the critical gap between diagnosis and therapy initiation. By utilizing digital onboarding and secure messaging, pharmacies can reduce the administrative burden—noting that traditional phone-based onboarding can take up to 45 minutes per patient. The experts demonstrated how digital workflows can streamline refill management and provide essential after-hours access, such as allowing a patient to share images of an infusion site reaction at 1:00 AM for immediate clinical guidance.

These tools ensure that pharmacists have a documented record of counseling and can focus their attention on nuanced patient needs rather than routine data collection. However, the speakers cautioned against using AI chatbots for high-risk clinical decisions, such as dosing advice, without strict clinical oversight. Ultimately, they emphasized a hybrid future where technology removes friction from the system. By automating administrative tasks like scheduling and triaging, clinicians are empowered to work at the top of their license, building the empathetic connections that drive long-term adherence. As demand and therapy complexity rise, this integration of digital efficiency and human oversight is viewed as the only sustainable path forward for specialty care.

Session 2: The Dawn of the Mega-Blockbuster Pharmaceutical Era

The pharmaceutical landscape is shifting into an era dominated by "mega-blockbusters"—drugs with annual sales exceeding $10 billion. Luke Greenwalt of IQVIA² highlighted that although the industry has seen massive success, with over 2000 product launches in 15 years, it now faces an unsettling trifecta of policy, including the Inflation Reduction Act (IRA), PBM reforms, and Most Favored Nation (MFN) pricing.

Despite these challenges, the market is highly concentrated; remarkably, 87% of sales growth between 2024 and 2025 came from just 25 branded drugs. The growth is primarily driven by oncology and obesity (GLP-1) therapies, with oncology seeing 500 launches and new indications in the last decade alone. However, this concentration creates a crowding out effect, where spending on a few elite brands reduces the budget for other new launches.

Simultaneously, the industry is bracing for a massive loss of exclusivity, with 32 brands representing over $1 billion in sales losing patent protection by 2030. This shift is expected to fuel a rise in biosimilars and direct-to-patient sales as retail pharmacies continue to close due to declining reimbursement. Policy changes are also reshaping distribution and costs. The Medicare Part D $2000 out-of-pocket cap is driving higher drug utilization, yet plans are responding with narrower formularies that restrict patient choice. Furthermore, the 340B Drug Pricing Program has ballooned to $84 billion in discounts as health systems aggressively expand their "child sites.”

“Mega-blockbuster brands crowd out other spending, and we start to see it as we look at the launch environment,” Greenwalt said.

Session 3: Rewriting the Pharmaceutical Commercial Model

In another session³, the experts challenged the industry's traditional focus on the prescribing encounter. Chris Moose of Wheel argued that the moment of clinical intent has moved upstream because modern patients arrive at appointments already self-diagnosed and informed by AI chatbots and large language models. Because these AI tools are persistent, they build a longitudinal understanding of the patient that often exceeds that of a traditional provider, meaning brands that only focus on the point of care are missing the window when a patient's opinion is actually formed.

“Patients are working with someone that has a longitudinal understanding, arguably better than the providers do about that patient, and that's what's going on with these AI [artificial intelligence] chatbots and LLMs [large language models],” Moose said in the session. “As people hook them into their health records, as they upload their health records, as they ask a question last week and come back today, the LLMs, because they're persistent, are building a longitudinal understanding, and that means the patient is getting better perspective and a more defined opinion about what's going on with their health care.”

To adapt, the industry must discard the assumptions that affordability equals access, that intent automatically translates into care, and that adherence is managed at the prescriber level. Instead of measuring success by script volume, manufacturers should focus on patient persistence and retention. Moose proposed a circular model of connected care where data-driven insights from virtual encounters continuously feed back into the patient relationship. He cited GLP-1 therapies as a prime example, where weight management serves as an "activation point" for patients to later engage in broader chronic care management.

This shift requires moving from transactional brand-level marketing to enterprise-level relationships. When patients identify with the manufacturer, they move from treating a single condition to engaging in comprehensive care. For pharmaceutical companies, this means building systems that convert initial digital intent into continuous clinical loops. Success in this new model is defined by retention over initiation, treating the patient relationship not as a one-time transaction but as the beginning of a long-term conversation.

REFERENCES

1. Steinzor P. Human-Centered Digital Transformation in Specialty Pharmacy. American Journal of Managed Care. April 28, 2026. Accessed April 29, 2026. https://www.ajmc.com/view/human-centered-digital-transformation-in-specialty-pharmacy

2. Wehrwein P. Retail blockbusters, then specialty drugs. Now a new era of mega-blockbusters | Asembia AXS26. Managed Healthcare Executive. April 29, 2026. Accessed April 29, 2026. https://www.managedhealthcareexecutive.com/view/a-new-era-of-mega-blockbusters-asembia-axs26

3. Steinzor P. How Virtual Care Is Rewriting the Direct-to-Patient Playbook. American Journal of Managed Care. April 28, 2026. Accessed April 29, 2026. https://www.ajmc.com/view/how-virtual-care-is-rewriting-the-direct-to-patient-playbook